Biote is a woman-led company operating a high growth, differentiated medical practice-building business within the hormone optimization space. Similar to a franchise model, Biote provides the necessary components to enable practitioners to establish, build, and successfully operate a hormone optimization center to treat patients appropriate for therapy. Biote trains practitioners how to identify and treat early indicators of hormone-related aging conditions.
Company profile
Ticker
BTMD
Exchange
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Haymaker Acquisition Corp. III
SEC CIK
BTMD stock data
Latest filings (excl ownership)
ARS
2023 FY
Annual report to shareholders
11 Apr 24
DEFA14A
Additional proxy soliciting materials
11 Apr 24
DEF 14A
Definitive proxy
11 Apr 24
424B3
Prospectus supplement
9 Apr 24
424B3
Prospectus supplement
9 Apr 24
S-8
Registration of securities for employees
4 Apr 24
EFFECT
Notice of effectiveness
3 Apr 24
EFFECT
Notice of effectiveness
3 Apr 24
POS AM
Prospectus update (post-effective amendment)
29 Mar 24
POS AM
Prospectus update (post-effective amendment)
29 Mar 24
Latest ownership filings
4
Teresa Sue Weber
3 Apr 24
4
Mary Elizabeth Conlon
3 Apr 24
4
Marc D Beer
3 Apr 24
SC 13G/A
Roystone Capital Management LP
14 Feb 24
SC 13G/A
Roystone Capital Management LP
14 Feb 24
SC 13G/A
Bandera Partners LLC
13 Feb 24
SC 13G/A
Boston Partners
13 Feb 24
SC 13G/A
LMR Partners LLP
12 Feb 24
4
Robert Charles Peterson
5 Feb 24
3
Robert Charles Peterson
31 Jan 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | |
---|---|---|---|
Revenue | |||
Cost of revenue | |||
Operating income | |||
Operating margin | |||
Net income | |||
Net profit margin | |||
Cash on hand | |||
Change in cash | |||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 65.58 mm | 65.58 mm | 65.58 mm | 65.58 mm | 65.58 mm | 65.58 mm |
Cash burn (monthly) | 968.33 k | 242.08 k | (no burn) | (no burn) | (no burn) | (no burn) |
Cash used (since last report) | 6.63 mm | 1.66 mm | n/a | n/a | n/a | n/a |
Cash remaining | 58.94 mm | 63.92 mm | n/a | n/a | n/a | n/a |
Runway (months of cash) | 60.9 | 264.0 | n/a | n/a | n/a | n/a |
Institutional ownership, Q3 2023
47.1% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 56 |
Opened positions | 11 |
Closed positions | 12 |
Increased positions | 18 |
Reduced positions | 13 |
13F shares | Current |
---|---|
Total value | 70.63 bn |
Total shares | 17.06 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
325 Capital | 3.77 mm | $19.29 bn |
Roystone Capital Management | 3.07 mm | $17.01 mm |
Bandera Partners | 1.71 mm | $8.73 bn |
Kent Lake Capital | 1.28 mm | $6.58 bn |
Wasatch Advisors | 1.23 mm | $6.30 bn |
Vanguard | 1.02 mm | $5.25 bn |
Boston Partners | 891.02 k | $4.56 bn |
Kanen Wealth Management | 837.64 k | $4.29 bn |
BLK Blackrock | 734.95 k | $3.76 bn |
SW Investment Management | 652.35 k | $3.34 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
1 Apr 24 | Teresa Sue Weber | Employee Stock Option Class A Common Stock | Grant | Acquire A | No | No | 5.72 | 777,083 | 4.44 mm | 2,669,663 |
1 Apr 24 | Mary Elizabeth Conlon | Employee Stock Option Class A Common Stock | Grant | Acquire A | No | No | 5.72 | 164,413 | 940.44 k | 422,574 |
1 Apr 24 | Marc D Beer | Employee Stock Option Class A Common Stock | Grant | Acquire A | No | No | 5.72 | 543,958 | 3.11 mm | 1,338,842 |
1 Feb 24 | Robert Charles Peterson | RSU Class A Common Stock | Grant | Acquire A | No | No | 0 | 44,250 | 0.00 | 44,250 |
1 Feb 24 | Robert Charles Peterson | Employee Stock Option Class A Common Stock | Grant | Acquire A | No | No | 4 | 400,000 | 1.60 mm | 400,000 |
News
12 Health Care Stocks Moving In Friday's After-Market Session
29 Mar 24
Roth MKM Reiterates Buy on Biote, Raises Price Target to $9
13 Mar 24
Biote Reaffirms 2024 Financial Guidance, With Acceleration In H2 Growth; Sees Revenue Of $200M-$204M, Est $203.167M; Adjusted EBITDA Of $60M-$63M
12 Mar 24
Biote: Q4 Earnings Insights
12 Mar 24
Biote Q4 2023 GAAP EPS $0.18 Beats $0.08 Estimate, Sales $45.703M Miss $45.740M Estimate
12 Mar 24